Has Jonathan Oren, MD received payments from drug or device companies?

Yes. Drug and device makers reported $40,337 in general payments to Jonathan Oren, MD across 110 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Oren, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Oren, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Oren, MD

Orthopaedic Surgery of the Spine · New York, NYNPI 1932333002

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Stryker at 53.7% of the total. 2025 is the largest year on record at $28,121, more than ten times the $779 reported in 2019.

$40,337in general payments, 2019–2025

Across 110 payments — averaging $366.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Stryker$22K
Premia Spine, Ltd.$7K
Intrinsic Therapeutics$4K
Alphatec Spine, Inc$4K
Globus Medical$1K
Johnson & Johnson$936
plus $2K from 11 others

$3,000in research payments, 2019–2025

Across 8 payments — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Intrinsic Therapeutics$3K

What the payments were for

Consulting fees$21,73354%
Speaking & faculty fees$6,75017%
Travel & lodging$7,65219%
Food & beverage$4,20210%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Stryker	30	$21,658
Premia Spine, Ltd.	1	$6,750
Intrinsic Therapeutics	2	$4,089
Alphatec Spine, Inc	8	$4,045
Globus Medical(2 entities)	4	$1,126
Johnson & Johnson	46	$936
Medtronic	6	$535
4web, Inc.	2	$284
Cerapedics Inc.	2	$206
Vertos Medical, Inc.	1	$168
Augmedics Inc.	2	$168
Solventum Corporation	1	$108
MML US, Inc.	1	$91
Relievant Medsystems, Inc.	1	$73
Providence Medical Technology, Inc.	1	$62
Centinel Spine, LLC	1	$25
Orthofix Medical, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

N/A$9,100
BARRICAID ACD (ANNULAR CLOSURE DEVICE)$8,065
TOPS$6,750
Other - Miscellaneous$2,533
ACCOLADE$2,100
MAKO$2,004
EVEREST SPINAL SYSTEM$1,411
EXCELSIUS$821
Xvision$631
MAZOR X SYSTEM$361
CASCADIA INTERBODY SYSTEM$287
SPINE TRUSS SYSTEM$284
LIF$208
EVEREST$175
mild Device Kit$168
LessRay$162
Modulus$162
RELINE$162
XLIF$162
GENERAL K2M PRODUCT DISCUSSION$159

How this compares

$40,337 in reported general payments places this provider in the 65th percentile of 161 orthopaedic surgery of the spine providers in New York.

See all orthopaedic surgery of the spine providers in New York →

Medicare billing

Part B allowed, 2024

$233,632

Medicare patients

310

Services billed

1,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Etodolac	26	$641
Methylprednisolone	38	$259
Meloxicam	42	$141
Gabapentin	22	$131
Methocarbamol	20	$127

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in New York

Frank SchwabNew York$5.1M
Han KimNew York$3.9M
Todd AlbertNew York$2.7M
Jeffrey SpivakNew York$1.3M
Aaron BucklandNew York$1M
Sheeraz QureshiNew York$828K
Jeffrey GoldsteinNew York$765K
Fabien BitanNew York$624K
Oheneba Boachie-AdjeiNew York$313K
Harvinder SandhuNew York$266K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →